Species B therefore represents an exciting avenue for development of oncolytics, however the lack of intrinsic tumour specificity and high prevalence of species B receptors, CD46 and DSG-2, on healthy cells is an important consideration that may result in the depletion of virotherapy available for active targeting of tumours through off-target sequestration. Here, CD46 is linked to neoplasm.